ReviewFrontiers in psychiatry2026
Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) remains one of the most frequently diagnosed mental health disorders and a leading cause of disability worldwide. The discovery of new treatments for MDD is necessary given up to 30% of individuals with MDD are resistant to current antidepressant treatments. The significant physiological interplay between MDD and metabolic conditions is crucial to consider for future therapeutics given the current obesity epidemic and the increased prevalence of treatment-resistant depression in individuals with metabolic dysfunction. The aim of this review is to discuss the relationship between metabolic dysfunction and MDD, while highlighting the potential antidepressant effects of insulin. There are interconnected perpetuating cycles involving hypothalamic-pituitary-adrenal (HPA) axis dysfunction, inflammation, obesity, insulin resistance, and MDD. Evidence on the efficacy of agents that target insulin resistance for depression is mixed and mechanisms by which these agents may improve depressive symptoms have not been clearly elucidated in studies reporting benefit. While there is a clear need to continue research on treatments that address the burden imposed by treatment-resistant depression, current data on whether insulin-sensitivity-targeting therapies can fill this gap remain limited. Clinically, routine metabolic screening in MDD could guide precision treatments targeting insulin pathways, particularly in those with metabolic dysfunction. Future studies considering the role of insulin, especially in those with insulin resistance, may enable development of novel therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.